The Technical Analyst
Athira Pharma, Inc. [ATHA]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Athira Pharma, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
0.26% $1.925
America/New_York / 26 apr 2024 @ 15:57
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 73.78 mill |
| EPS: | -3.09 |
| P/E: | -0.620 |
| Earnings Date: | May 09, 2024 |
| SharesOutstanding: | 38.33 mill |
| Avg Daily Volume: | 0.355 mill |
| RATING 2024-04-26 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Sell | |
| P/E: | Neutral | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.620 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.11x |
| Company: PE -0.620 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$2.34 (21.60%) $0.416 |
| Date: 2024-04-26 |
| Expected Trading Range (DAY) |
|---|
|
$ 1.693 - 2.15 ( +/- 11.91%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-15 | San Martin Javier | Buy | 400 000 | Stock Option (Right to Buy) |
| 2024-04-15 | San Martin Javier | Buy | 0 | |
| 2024-02-15 | Litton Mark James | Buy | 650 000 | Stock Option (Right to Buy) |
| 2024-02-14 | Worthington Mark | Buy | 220 000 | Stock Option (Right to Buy) |
| 2024-02-14 | Church Kevin | Buy | 220 000 | Stock Option (Right to Buy) |
| INSIDER POWER |
|---|
| 98.60 |
| Last 99 transactions |
| Buy: 6 665 546 | Sell: 65 252 |
Forecast:
16:00 - $1.925
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $1.925
Forecast 2: 16:00 - $1.925
Forecast 3: 16:00 - $1.925
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.925 (0.26% ) |
| Volume | 0.143 mill |
| Avg. Vol. | 0.355 mill |
| % of Avg. Vol | 40.27 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ATHA
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:34 | buy | $3.15 | N/A | Active |
|---|
ATHA
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease. It also develops product candidates, which are in preclinical stage, including ATH-1019 for peripheral nervous system indications; and ATH-1020 for neuropsychiatric conditions. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.
Latest Press Releases
2024-04-15 07:00:00 - Press Release
Athira Pharma Appoints Javier San Martin, M.d., As Chief Medical Officer
Bothell, wash., april 15, 2024 (globe newswire) -- athira pharma, inc. (nasdaq: atha), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the appointment of javier san martin, m.d.
2024-04-11 07:00:00 - Press Release
Athira Pharma Announces Publication Of Preclinical Data Highlighting Fosgonimeton Treatment In Models Of Alzheimer's Disease
Bothell, wash., april 11, 2024 (globe newswire) -- athira pharma, inc. (nasdaq: atha), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the publication of preclinical data supporting the therapeutic potential of fosgonimeton in alzheimer's disease.
2024-04-03 07:00:00 - Press Release
Athira Pharma Announces Upcoming Poster Presentation At American Academy Of Neurology (aan) 2024 Annual Meeting
Presentation to highlight therapeutic potential of athira's small molecules targeting the neurotrophic hgf system in neurodegenerative disorders, including alzheimer's disease, parkinson's disease and amyotrophic lateral sclerosis presentation to highlight therapeutic potential of athira's small molecules targeting the neurotrophic hgf system in neurodegenerative disorders, including alzheimer's disease, parkinson's disease and amyotrophic lateral sclerosis
2024-03-08 07:00:00 - Press Release
Athira Pharma Presents Clinical And Preclinical Data Supporting Therapeutic Potential Of Fosgonimeton In Alzheimer's And Parkinson's Diseases At Ad/pd™ 2024 International Conference
Athira pharma presents clinical and preclinical data supporting therapeutic potential of fosgonimeton in alzheimer's & parkinson's diseases at ad/pd™ 2024
2024-02-22 16:05:00 - Press Release
Athira Pharma Reports Full Year 2023 Financial Results And Pipeline And Business Updates
Enrollment completed in phase 2/3 lift-ad clinical trial of fosgonimeton as a potential treatment for mild-to-moderate alzheimer's disease; topline data expected in second half of 2024 on track to initiate first-in-human studies of ath-1105 for the treatment of amyotrophic lateral sclerosis in first half of 2024 strong balance sheet to support innovative pipeline through key inflection points bothell, wash., feb. 22, 2024 (globe newswire) -- athira pharma, inc. (nasdaq: atha), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today reported financial results for the year ended december 31, 2023, and reviewed recent pipeline and business updates.
Latest News
2024-02-28 13:01:06 - Zacks Investment Research
Athira Pharma, Inc. (ATHA) is a Great Momentum Stock: Should You Buy?
Does Athira Pharma, Inc. (ATHA) have what it takes to be a top stock pick for momentum investors? Let's find out.
2023-12-01 08:15:06 - MarketBeat
These biotechs targeting multiple neurodegenerative diseases
Anyone who has struggled with a neurodegenerative disease (NDD) or has cared for someone who has one of these illnesses knows how challenging they are to treat and even diagnose. NDDs damage cognitive functions, motor functions, or sometimes both.
2023-11-29 07:00:00 - GlobeNewsWire
Athira Pharma to Participate in Sidoti December Small Cap Investor Conference
Company Presentation to highlight novel therapeutic candidates targeting the HGF neurotrophic system in late-stage clinical development in neurodegenerative diseases, including Alzheimer's disease Company Presentation to highlight novel therapeutic candidates targeting the HGF neurotrophic system in late-stage clinical development in neurodegenerative diseases, including Alzheimer's disease
2023-09-19 07:00:00 - GlobeNewsWire
Athira Pharma to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference
BOTHELL, Wash., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that Company management will participate in a panel presentation at the 2023 Cantor Fitzgerald Global Healthcare Conference taking place from September 26-28, 2023 in New York City. Details are as follows:
2023-09-08 13:32:39 - Zacks Investment Research
All You Need to Know About Athira Pharma, Inc. (ATHA) Rating Upgrade to Buy
Athira Pharma, Inc. (ATHA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
2023-08-31 11:18:06 - Zacks Investment Research
Down -24.75% in 4 Weeks, Here's Why You Should You Buy the Dip in Athira Pharma, Inc. (ATHA)
Athira Pharma, Inc. (ATHA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
2023-05-08 07:00:00 - GlobeNewsWire
Athira Pharma to Participate in Upcoming May Investor Conferences
BOTHELL, Wash., May 08, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that it will participate in the following upcoming investor conferences:
2023-03-28 13:44:15 - Zacks Investment Research
Athira Pharma, Inc. (ATHA) Upgraded to Buy: What Does It Mean for the Stock?
Athira Pharma, Inc. (ATHA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
2023-03-06 07:00:00 - GlobeNewsWire
Athira Pharma to Present Data Supporting Therapeutic Potential of Enhancing HGF/MET Neurotrophic System at Upcoming Scientific Conferences
BOTHELL, Wash., March 06, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that it will participate in two upcoming scientific conferences: American Society for Experimental Neurotherapeutics (ASENT) 2023 Annual Meeting, which will be held virtually from Mar. 13-15, 2023, and AD/PD™ 2023 International Conference on Alzheimer's and Parkinson's Diseases (AD/PD), which will be held in Gothenburg, Sweden and virtually from Mar. 28-Apr. 1, 2023.
2022-11-28 07:00:00 - GlobeNewsWire
Athira Pharma to Present Preclinical Data Highlighting Therapeutic Potential of ATH-1105 in ALS at the 33rd International Symposium on ALS/MND
HGF/MET small molecule positive modulator provides neuroprotection and improves motor and nerve function in a TDP-43 mouse model of ALS HGF/MET small molecule positive modulator provides neuroprotection and improves motor and nerve function in a TDP-43 mouse model of ALS